Newsroom

Sorted by: Latest

-

Bella Maison, the Brand Behind Turkish Cotton, Launches in the US

NEW YORK--(BUSINESS WIRE)--Bella Maison, the brand behind Turkish cotton, launches in the US with design-led home collections and a distinct style perspective....
-

Land & Buildings Sends Letter to First Industrial Realty Trust Shareholders Highlighting the Need for Shareholders to Send a Clear Message That Further Change is Required

STAMFORD, Conn.--(BUSINESS WIRE)--Today, Land & Buildings Investment Management, LLC (together with its affiliates, “Land & Buildings,” “L&B,” “us” or “we”), a shareholder of First Industrial Realty Trust, Inc. (NYSE: FR) (“First Industrial,” “FR” or the “Company”), issued a letter to shareholders responding to the Company’s glossy mailer and highlighting that FR’s belated concessions prove the campaign is working but that changes fall far short of what shareholders deserve. The ful...
-

Stratasys Unleashes New Innovations Across its Hardware, Software, and Materials Platform to Power Additive Manufacturing

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) announced today that it has expanded its portfolio of additive manufacturing solutions across multiple industries with the introduction of new software and materials that expand applications of existing systems and improve ease of use for customers. New materials include: ULTEM™ 1010 filament for the F3300® printer, and PolyJet ToughONE™ White for Stratasys J3/J5™ printers, along with a new Measurement-Based War...
-

Perma-Pipe International Holdings, Inc. Announces the Appointment of Nancy Zakhour and Saleh Sagr to its Board of Directors

THE WOODLANDS, Texas--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in pre-insulated piping and leak detection systems, today announced the appointment of Nancy Zakhour and Saleh Sagr to its Board of Directors, effective April 8, 2026. Ms. Zakhour will serve as an independent director and a member of the Board’s Audit, Compensation, and Nominating and Corporate Governance Committees. Mr. Sagr will serve as a director. Ms. Zakhour is a dynamic energy ex...
-

Le Fonds saoudien pour le développement signe un accord de 15 millions de dollars avec la République des Palaos pour stimuler la croissance économique locale

NGERULMUD, République des Palaos--(BUSINESS WIRE)--Saudi Fund for Development Signs USD 15 Million Agreement with the Republic of Palau to Drive Local Economic Growth...
-

Pathward Recognized for Digital Banking Innovation in 10th Annual FinTech Breakthrough Awards Program

SIOUX FALLS, S.D.--(BUSINESS WIRE)--Pathward announced that it has been selected as “Banking-as-a-Service Platform of the Year” in the 10th annual FinTech Breakthrough Awards program....
-

Populus Health Technologies Partners with Patients, Physicians and Pharma Marketers to Create the First Comprehensive Report on Virtual Care in America

PRINCETON, N.J.--(BUSINESS WIRE)--Populus Health Technologies (Populus), a virtual care media and technology company, has partnered to create an in depth understanding of patients, HCPs and pharma marketers' views on virtual care: “Virtual Care in America: The Populus Report.” The report will establish the benefits and opportunities facing three key stakeholders as the virtual healthcare environment continues to evolve. It will provide a clear-eyed, multi-perspective view of how virtual care is...
-

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the MHRA has accepted the submission of the MOLBREEVI MAA for the treatment of autoimmune PAP in the U.K. The MAA was accepted under Accelerated Review and qualifies for a 150-day assessment duration. A decision on the application is expected in Q4 2026. In the U.S., the FDA is reviewing the MOLBREEVI BLA under Priority...
-

Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars

BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)--Biocon announced the launch of Bosaya™ and Aukelso™ (denosumab-kyqq) in the U.S. and available by prescription nationwide....
-

Morningstar DBRS Marks 50 Years of Credit Ratings; Advances Global Methodology Program and Asia-Pacific Growth

TORONTO--(BUSINESS WIRE)--Morningstar DBRS marks 50 years of credit ratings, advances global methodology program and Asia-Pacific growth....